Abstract: An implantable device for intratumoral delivery of a therapeutic agent is provided. The implantable device includes a polymer matrix within which is dispersed a pharmaceutical formulation that includes one or more therapeutic agents. The therapeutic agent(s) includes one or more antibodies. Optionally, the polymer matrix includes one or more excipients. The polymer matrix includes a hydrophobic polymer. The hydrophobic polymer has a melt flow index of from about 0.2 to about 100 grams per 10 minutes as determined in accordance with ASTM D1238-20 at a temperature of 190° C. and a load of 2.16 kilograms and/or a melting temperature of from about 20° C. to about 70° C. as determined in accordance with ASTM D3418-21.

Abstract: An implantable medical device is provided. The core includes a core polymer matrix within which is dispersed a therapeutic agent comprising one or more aromatase inhibitors. The core polymer matrix contains an ethylene vinyl acetate copolymer. The ethylene vinyl acetate copolymer has a melting temperature of from about 40° C. to about 120° C. as determined in accordance with ASTM D3418-15.

Abstract: An intravaginal ring device is provided. The core includes a core polymer matrix within which is dispersed a therapeutic agent comprising one or more aromatase inhibitors. The core polymer matrix contains an ethylene vinyl acetate copolymer. The ethylene vinyl acetate copolymer has a vinyl acetate content of from about 10 wt. % to about 60 wt. % and/or a melting temperature of from about 40° C. to about 120° C. as determined in accordance with ASTM D3418-15.

Abstract: A method for making an elongate medical device includes coupling a conductive fitting to an elongate conductor and providing an opening through an insulative layer in proximity to the fitting in order to expose the fitting.